Brief summary describing the background
and objectives of the trial
|
After obtaining Institutional Ethical Committee approval and written informed consent, this prospective randomized double blind controlled study conducted on 90 adult patients aged 18-70 years, of American Society of Anesthesiologists (ASA) physical status I to III, scheduled for emergency laparotomies, ,under general anesthesia will be included in this study. According to the used medications, the patiants allocated into 3 groups (30 patients on each group). Group I (C group): received 40 ml bupivacine 0.25% (20 ml on each side ). Group II (D group): received 8 mg dexamethason (2ml) + 38 ml bupivacine 0.25% (20 ml on each side ). Group III (M group): received 200 mg magnesium sulphate (2 ml ) + 38 8 ml bupivacine 0.25% (20 ml on each side ). The studded medication prepared and supplied in similar syringe by an anesthetist not included in the management of the patient or data collection. Following placement of the standard monitors, induction of anesthesia, stabilizing the patient¿s hemodynamics, and before surgical incision, TAP block performed Parameters assessed: pre operative period: 1. Basal MAP,HR. Intra operative period: 1.BP,HR after induction and at 15,30,45,60,90 min after local anesthetic infilteration then every half an hour till end of surgery. 2. Total intraoperative fentanyl requirement post operative period: 1. Haemodynamic parameters including BP and HR at 1, 2,4,8,12,18,24hrs. 2.Visual analogue pain score at 1,2,4,8,12, 18,24hrs. 3. Onset and duration of analgesia. 4.Time of first analgesic request. 5.Total analgesic requirement over 1st 24 hrs. 6.side effect. 7.Time of discharge from postoperative anesthetic care unit we found that Adding dexamethasone or magnesium to bupivacaine produce lower VAPs, delayed the time of first analgesic request, decreased the total amount of postoperative analgesics and more hemodynamic stability in comparison to bupivacaine alone and magnesium sulfate was superior over dexamethasone.
|